Drug Profile
Interferon beta-1a - Biogen
Alternative Names: Avonex; Avonex Pen; IFN-b-1a; Interferon β-1aLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Biogen Idec
- Developer Biogen; Eisai Co Ltd; Merck & Co; Nektar Therapeutics
- Class Antiasthmatics; Antineoplastics; Antivirals; Interferons; Vascular disorder therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple sclerosis
- Discontinued Chronic inflammatory demyelinating polyradiculoneuropathy; Glioma; Hepatitis B; Hepatitis C; Human papillomavirus infections; Pulmonary fibrosis; Ulcerative colitis
Most Recent Events
- 01 Apr 2021 No development reported - Phase-II for Multiple sclerosis (Adjunctive treatment) in Italy (SC) (Biogen pipeline, April 2021)
- 06 Feb 2020 Merck KGaA terminates the phase II INCREASE trial in Multiple sclerosis (Adjunctive treatment) in Italy due to slow recruitment (SC) (NCT03387046)
- 11 Jan 2019 Merck KGaA completes the phase-II INCREASE trial in Multiple sclerosis in Italy (NCT03387046)